InMode (NASDAQ:INMD) Updates Q1 2022 Earnings Guidance

InMode (NASDAQ:INMDGet Rating) issued an update on its first quarter 2022 earnings guidance on Monday morning. The company provided earnings per share guidance of $0.380-$0.390 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.360. The company issued revenue guidance of $85 million-$85.50 million, compared to the consensus revenue estimate of $80.05 million.

InMode stock opened at $30.40 on Monday. InMode has a 52 week low of $30.10 and a 52 week high of $99.27. The firm’s 50-day simple moving average is $39.55 and its 200 day simple moving average is $60.37. The firm has a market capitalization of $2.53 billion, a PE ratio of 15.83 and a beta of 1.92.

InMode (NASDAQ:INMDGet Rating) last released its quarterly earnings data on Thursday, February 10th. The healthcare company reported $0.60 EPS for the quarter. InMode had a net margin of 46.14% and a return on equity of 46.14%. The business had revenue of $110.50 million for the quarter, compared to analyst estimates of $103.54 million. During the same period in the previous year, the firm earned $0.94 EPS. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year.

Separately, Needham & Company LLC cut their target price on shares of InMode from $103.00 to $82.00 and set a buy rating for the company in a research note on Friday, February 11th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of Buy and a consensus target price of $90.75.

Several hedge funds and other institutional investors have recently bought and sold shares of INMD. BlackRock Inc. increased its stake in shares of InMode by 121.6% during the 4th quarter. BlackRock Inc. now owns 2,160,940 shares of the healthcare company’s stock valued at $152,520,000 after acquiring an additional 1,185,834 shares during the last quarter. State Street Corp increased its stake in shares of InMode by 356.0% during the 4th quarter. State Street Corp now owns 773,835 shares of the healthcare company’s stock valued at $54,617,000 after acquiring an additional 604,141 shares during the last quarter. Legal & General Group Plc increased its stake in shares of InMode by 2,800.8% during the 4th quarter. Legal & General Group Plc now owns 364,916 shares of the healthcare company’s stock valued at $25,756,000 after acquiring an additional 352,336 shares during the last quarter. Deutsche Bank AG increased its stake in shares of InMode by 26,633.4% during the 4th quarter. Deutsche Bank AG now owns 347,534 shares of the healthcare company’s stock valued at $24,528,000 after acquiring an additional 346,234 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of InMode by 223.3% during the 4th quarter. Geode Capital Management LLC now owns 326,050 shares of the healthcare company’s stock valued at $22,943,000 after acquiring an additional 225,192 shares during the last quarter. 35.23% of the stock is owned by institutional investors.

InMode Company Profile (Get Rating)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Recommended Stories

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.